Biologics and Small-Molecule Inhibitors for the Treatment of Nummular Eczema: A Systematic Review

Nummular eczema (NE) is a chronic, pruritic dermatitis with substantial patient burden and no FDA-approved therapies. Emerging data suggest that biologics and small-molecule inhibitors may be promising therapeutic options for NE.

On October 29, 2025, PubMed, Embase, and the Cochrane Library were searched using PRISMA guidelines for English-language human clinical studies and cases evaluating biologics and small-molecule inhibitors for the treatment of NE.